ENZYMATICA Aktie

 

Enzymatica AB (publ) announces today that the company's Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her position. The decision has been made in mutual agreement between Therese Filmersson and the company's Board of Directors. – During her time as CFO, Therese has contributed very positively to the development of the company. We thank her for her efforts and wish her all the best in her future endeavors, says Claus Egstrand, CEO of Enzymatica AB. Therese Filmersson will remain in her role during the notice period to ensure a smooth transition. The...

The CEO of Enzymatica AB, Claus Egstrand, is stepping down from his role and will join the company's Board of Directors. Recruitment of a new CEO has begun. The change will ensure long-term stability in the company's leadership as it prepares for international expansion. Following the publication of  the strong research results for ColdZyme in The Journal of Physiology in February this year, efforts have intensified to sign international distribution agreements. In order to ensure longer term continuity in these discussions and partnerships, Claus Egstrand has decided to step down from his...

Enzymatica AB (publ) held its annual general meeting on May 7, 2024. At the annual general meeting, the following resolutions were made. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Enzymatica AB (publ) held its annual general meeting on 7 May 2025. At the annual general meeting, the following resolutions were made. Income statements and balance sheets The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income...

In the first quarter, Enzymatica achieved a 30.3 per cent increase in net sales, reaching SEK 12.3 million. The strongest growth was recorded in Sweden and the United Kingdom, while partner-driven sales in other markets remained absent. The company is now accelerating efforts to secure new partnership agreements aimed at expanding ColdZyme's presence in additional international market. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/05/enzymatica-gears-up-for-global-expansion-after-a-strong-first-quarter/ This is a press release from...

LUND, Sweden, April 29, 2025 /PRNewswire/ -- First quarter Net sales amounted to SEK 12.3 million (9.4). Operating result amounted to SEK -18.0 million (-18.4). Earnings per share, before and after dilution, amounted to SEK -0.07 (-0.11). Cash flow from operating activities amounted to......

The annual general meeting of Enzymatica AB (publ), reg. no. 556719-9244, will be held on 7 May 2025 at 14:30 CEST, Elite Hotel Ideon, Scheelevägen 27 in Lund. Notification etc. Those who wish to participate in the annual general meeting must: (i)      be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 28 April 2025; and (ii)     give notice of intent to participate no later than 2 May 2025. Notification shall be made either in writing to Enzymatica AB, Att: Sriwarint Olsson,...

Study results show that Enzymatica's mouth spray, ColdZyme, reduces viral load and inhibits its spread, leading to fewer sick days and milder symptoms. The study findings have now been published in the highly ranked journal The Journal of Physiology. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/03/enzymaticas-results-published-in-the-journal-of-physiology/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se...

In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB held a digital press conference on March 5, 2025. The press conference is available for replay at the following link: https://creo-live.creomediamanager.com/eda7c0f6-7107-4d87-b409-82bdf2d58605   Read the press release published 28 February here: https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/ Link to the published article in The Journal of...

STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing on 5 March 2025. 13:00–14:10 The researchers will present their findings and be available for......

In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing on 5 March 2025. · 13:00–14:10 The researchers will present their findings and be available for questions · 14:15–15:00 Enzymatica's CEO, Claus Egstrand, and Chairman, Bengt Baron, will present a company overview and be available for questions The press briefing will be broadcast live. To participate in the live discussion, please register via this link: https://creo-live.creomediamanager.com/eda7c0f6-7107-4d87-b409-82bdf2d58605 (https://...

The cold season is in full swing, which is also reflected in Enzymatica's fourth-quarter report, showing increased sales compared to the same period in 2023. However, full-year revenue declined compared to the previous year, primarily due to the absence of sales through partners. BioStock reached out to the company's CEO, Claus Egstrand, to learn more. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/02/enzymatica-boosts-q4-revenue-but-sees-room-for-stronger-partner-sales/ This is a press release from BioStock - Connecting Innovation &...

Enzymatica strengthens its growth strategy by recruiting Anna Söderlund as Senior Director of Marketing & Sales. With extensive experience in the life science industry as well as in sales and marketing, Anna brings valuable expertise to the company. – Enzymatica has an incredibly exciting product in ColdZyme, and I look forward to helping more consumers discover it. Products that can be marketed directly to the end user are both interesting and rewarding to work with. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/01/enzymatica-...

Enzymatica AB (publ) announces today that Anna Söderlund has joined as the new Senior Director Marketing & Sales. With over 25 years of experience in the Life Science industry, where she has held leading roles at global companies such as Pfizer and MSD, Anna brings solid expertise to the company. – We are very pleased to welcome Anna Söderlund to Enzymatica. We are in an expansive phase with a strong focus on driving sales growth. Anna's long experience, strategic acumen, and commitment will be crucial to our continued success, says Claus Egstrand, CEO of Enzymatica. Anna Söderlund holds...

LUND, Sweden, Nov. 7, 2024 /PRNewswire/ -- Third quarter January-September Net sales reached SEK 12.6 (13.3) million. The operating result totaled SEK -6.4 (-8.7) million. Earnings per share, basic and diluted, were SEK -0.04 (-0.06). Cash flow from operating activities totaled SEK -13.6......

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (”Enzymatica” or ”Company”) today announces the outcome of the new share issue with preferential rights for existing shareholders that was resolved by the Board of Directors on July 18, 2024, and...

An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica's mouth spray ColdZyme reduces the duration of upper respiratory tract infections by up to five days in endurance athletes, enabling faster return to training. Additionally, ColdZyme alleviates symptoms and decreases the viral load of rhinovirus, the most common cause of a cold. Principal investigator Glen Davison shared insights on these results in an interview with BioStock. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2024/09/final-study-...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (“Enzymatica” or “Company”) has issued a supplement (the “Supplementary Prospectus”) in addition to the EU growth prospectus that has been approved and registered by the Swedish Financial...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The prospectus (the “Prospectus”) for Enzymatica AB's rights issue of around SEK 130 million (the “Rights issue”) has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The...

Das Instrument EN9 SE0003943620 ENZYMATICA AB EQUITY wird cum Kapitalmassnahme gehandelt am 22.08.2024 und ex Kapitalmassnahme am 23.08.2024 The instrument EN9 SE0003943620 ENZYMATICA AB EQUITY is traded cum capital adjustment on 22.08.2024 and ex capital adjustment on 23.08.2024...

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. LUND, Sweden, Aug. 6, 2024 /PRNewswire/ -- The shareholders of Enzymatica AB (publ) (the "Company") held an extraordinary......